CollPlant Biotechnologies Ltd
Business
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company developing innovative plant-based recombinant human collagen (rhCollagen) technology and products. The company produces rhCollagen through genetically engineered tobacco plants and manufactures rhCollagen-based bioinks, dermal fillers, breast implants, and soft tissue repair matrices for medical aesthetics and tissue regeneration applications. CollPlant operates through internal product development, licensing arrangements with partners including AbbVie, and commercialization of bioink products including the Collink.3D platform, serving markets in regenerative medicine, aesthetic procedures, orthobiologics, and 3D bioprinting of tissues and organs globally.
Summary from 20-F filed 2026-03-26
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | $2.37M |
| Net income | $-11.49M |
| Total assets | $10.79M |
| Total liabilities | $4.70M |
| Stockholders' equity | $6.08M |
| Operating cash flow | $-9.42M |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is CollPlant Biotechnologies Ltd's CIK number?
CollPlant Biotechnologies Ltd's SEC CIK number is 0001631487 (1631487). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find CollPlant Biotechnologies Ltd's SEC filings?
All of CollPlant Biotechnologies Ltd's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.